An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions

Abstract

The skeleton is the most common metastatic organ in patients with prostate cancer (PCa). Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed this study to assess the expression patterns of serum miR-141 in patients with bone-metastatic PCa. Serum samples were collected to measure the miR-141 level in 56 patients, including six with benign prostatic hyperplasia (BPH), 20 with localized PCa and 30 with bone-metastatic PCa (10 with hormone-naive PCa, 10 with hormone-sensitive PCa and 10 with hormone-refractory PCa). A bone scan was performed for each patient with PCa to assess the number of bone lesions. The quantification of serum miR-141 levels was assayed by specific TaqMan qRT-PCR. The results showed that serum miR-141 levels were elevated in patients with bone metastasis (P,0.001). There was no statistically significant difference in the serum miR-141 levels between patients with BPH and patients with localized PCa. Using Kendall's bivariate correlation test, both the Gleason score and the number of bone-metastatic lesions were found to correlate with serum miR-141 levels (P50.012 and P,0.001, respectively). The serum miR-141 level was found to be positively correlated with alkaline phosphatase (ALP) level in patients with skeletal metastasis, using Pearson's bivariate correlation test. No relationship was found between the serum miR-141 level and the serum prostate-specific antigen (PSA) level. We concluded that serum miR-141 levels are elevated in patients with bone-metastatic PCa and that patients with higher levels of serum miR-141 developed more bone lesions. Furthermore, serum miR-141 levels are correlated with serum ALP levels but not serum PSA levels.

Analysis of circulating miRNAs 21 and 375 as potential biomarkers for early diagnosis of prostate cancer

“…It has been reported that expression patterns of miRNAs can distinguish patients from healthy individuals and the expression characteristics are associated with the developmental lineage of the cancer and of the disease stage [7,8]. Circulating miRNAs have been evaluated as potential noninvasive biomarkers for PCa [4,[9][10][11]. However, the findings are not conclusive.…”

“…The sensitivity is low and the optimal threshold for biopsy is unclear [3]. On the one hand many patients were over diagnosed due to negative positivity, on the other hand most patients (70 %) are diagnosed at the late stages of PCa and lose the best chances for early treatments [4]. Hence, there is more and more interest in searching for alternative noninvasive biomarkers such as miRNAs.…”

miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression

“…Zhang et al reported that miR-141 can predict tumor progression in prostate cancer (28). Also, high miR-141 plasma level is associated with poor prognosis in colorectal cancer and was proposed as a novel biomarker to find distant metastases (15).…”

MicroRNA: sex steroids, hormonal carcinogenesis, hormonal sensitivity of tumor tissue

“…Например, андроген вызывает активацию экспрессии miR-141 в клетках РПЖ in vitro (LNCaP, VCaP) и in vivo [29]. С другой стороны, в ряде независимых исследований повышение уровня этой микроРНК было показано в плазме больных РПЖ [36,37]. С учетом роли экзо-сомальной микроРНК в процессе опухолевой диссе-минации [38], андроген-регулируемые сдвиги профи-ля экспрессии микроРНК клетками РПЖ могут иметь значение в процессе формирования отдаленных мета-стазов [39].…”